Literature DB >> 27699465

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Anja Thormann1,2, Melinda Magyari3,4, Nils Koch-Henriksen4,5, Bjarne Laursen6, Per Soelberg Sørensen3.   

Abstract

To investigate the occurrence of vascular comorbidities before and after the clinical onset of multiple sclerosis. In this combined case-control and cohort study, all Danish born citizens with onset of multiple sclerosis 1980-2005 were identified from the Danish Multiple Sclerosis Registry and randomly matched with controls regarding year of birth, gender, and municipality on January 1st in the year of multiple sclerosis (MS) onset (index date). Individual-level information on comorbidities was obtained from several independent nationwide registries and linked to the study population by unique personal identification numbers. To assess the presence of vascular comorbidities before and after MS onset, cases and controls were followed from January 1977 to the index date, and from the index date through December 2012. We used logistic regression to calculate odds ratios (ORs) and Cox regression to calculate hazard ratios (HRs). Before the index date, MS cases had a decreased probability for cerebrovascular comorbidity [OR 0.69 (95 % CI 0.48-0.99, p = 0.043)], and a numerically but not statistically significant decreased probability for cardiovascular comorbidity [OR 0.87 (95 % CI 0.71-1.07, p = 0.188)]. After the index date, MS cases had an increased risk for cerebrovascular comorbidity [HR 1.84 (95 % CI 1.69-2.00, p < 0.0005)], and for cardiovascular comorbidity [HR 1.08 (95 % CI 1.02-1.15, p = 0.013)]. The lower occurrence of cerebrovascular comorbidities in cases prior to MS onset could be due to protective immune mechanisms, while the higher occurrence of vascular comorbidities in cases after MS onset could be because of converging causal pathways of the coexisting diseases. These findings deserve to be studied closer in a broader spectrum of comorbidities in MS.

Entities:  

Keywords:  Comorbidity; Epidemiology; Multiple sclerosis; Vascular comorbidity

Mesh:

Year:  2016        PMID: 27699465     DOI: 10.1007/s00415-016-8295-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  46 in total

1.  Smoking is a major preventable risk factor for multiple sclerosis.

Authors:  A K Hedström; T Olsson; L Alfredsson
Journal:  Mult Scler       Date:  2015-10-12       Impact factor: 6.312

2.  Physical activity and multiple sclerosis: a meta-analysis.

Authors:  Robert W Motl; Edward McAuley; Erin M Snook
Journal:  Mult Scler       Date:  2005-08       Impact factor: 6.312

3.  Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study.

Authors:  Ruth Ann Marrie; Bo N Yu; Stella Leung; Lawrence Elliott; Patricia Caetano; Sharon Warren; Christina Wolfson; Scott B Patten; Lawrence W Svenson; Helen Tremlett; John Fisk; James F Blanchard
Journal:  Mult Scler Relat Disord       Date:  2013-04-02       Impact factor: 4.339

4.  Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.

Authors:  Mads Ravnborg; Per Soelberg Sørensen; Magnus Andersson; Elisabeth G Celius; Peter J Jongen; Irina Elovaara; Emmanuel Bartholomé; Cris S Constantinescu; Karsten Beer; Ellen Garde; Bjørn Sperling
Journal:  Lancet Neurol       Date:  2010-06-09       Impact factor: 44.182

5.  Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study.

Authors:  H Roshanisefat; S Bahmanyar; J Hillert; T Olsson; S Montgomery
Journal:  Eur J Neurol       Date:  2014-07-17       Impact factor: 6.089

6.  Comorbidities amongst patients with multiple sclerosis: a population-based controlled study.

Authors:  J-H Kang; Y-H Chen; H-C Lin
Journal:  Eur J Neurol       Date:  2010-02-23       Impact factor: 6.089

7.  Vascular disease among hospitalized multiple sclerosis patients.

Authors:  Norrina B Allen; Judith H Lichtman; Hillel W Cohen; Jing Fang; Lawrence M Brass; Michael H Alderman
Journal:  Neuroepidemiology       Date:  2008-04-25       Impact factor: 3.282

8.  The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients.

Authors:  Sandra K Thygesen; Christian F Christiansen; Steffen Christensen; Timothy L Lash; Henrik T Sørensen
Journal:  BMC Med Res Methodol       Date:  2011-05-28       Impact factor: 4.615

9.  Chronic diseases in male veterans with multiple sclerosis.

Authors:  Sherri L Lavela; Thomas R Prohaska; Sylvia Furner; Frances M Weaver
Journal:  Prev Chronic Dis       Date:  2012-02-09       Impact factor: 2.830

10.  Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.

Authors:  Ali Manouchehrinia; Christopher R Tench; Jonathan Maxted; Rashid H Bibani; John Britton; Cris S Constantinescu
Journal:  Brain       Date:  2013-06-11       Impact factor: 13.501

View more
  8 in total

1.  Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis.

Authors:  Tomaž Omerzu; Jožef Magdič; Radovan Hojs; Uroš Potočnik; Mario Gorenjak; Tanja Hojs Fabjan
Journal:  Wien Klin Wochenschr       Date:  2021-04-26       Impact factor: 1.704

2.  Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden.

Authors:  Anna Castelo-Branco; Flaminia Chiesa; Camilla E Bengtsson; Sally Lee; Neil N Minton; Steve Niemcryk; Anders Lindholm; Mats Rosenlund; Fredrik Piehl; Scott Montgomery
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-08-14

3.  Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis.

Authors:  P Belov; D Jakimovski; J Krawiecki; C Magnano; J Hagemeier; L Pelizzari; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

Review 4.  Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis.

Authors:  Joanna Saluk-Bijak; Angela Dziedzic; Michal Bijak
Journal:  Cells       Date:  2019-02-01       Impact factor: 6.600

5.  Unique RNA signature of different lesion types in the brain white matter in progressive multiple sclerosis.

Authors:  Maria L Elkjaer; Tobias Frisch; Richard Reynolds; Tim Kacprowski; Mark Burton; Torben A Kruse; Mads Thomassen; Jan Baumbach; Zsolt Illes
Journal:  Acta Neuropathol Commun       Date:  2019-04-25       Impact factor: 7.801

6.  Multiple Sclerosis and the Risk of Cardiovascular Diseases: A Mendelian Randomization Study.

Authors:  Fangkun Yang; Teng Hu; Kewan He; Jiajun Ying; Hanbin Cui
Journal:  Front Immunol       Date:  2022-03-15       Impact factor: 7.561

7.  Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

Authors:  João J Cerqueira; D Alastair S Compston; Ruth Geraldes; Mario M Rosa; Klaus Schmierer; Alan Thompson; Michela Tinelli; Jacqueline Palace
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-04-04       Impact factor: 10.154

8.  The Danish Multiple Sclerosis Registry.

Authors:  Melinda Magyari; Hanna Joensen; Bjarne Laursen; Nils Koch-Henriksen
Journal:  Brain Behav       Date:  2020-10-30       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.